



**ASX ANNOUNCEMENT**

**14 February 2019**

## **Major Brazilian health care group places initial pilot order with HeraMED**

- **Following rigorous technical and medical testing an initial order for 100 HeraBEAT, smart ultrasound foetal heart rate monitors has been placed by Hapvida – order includes software development kit and ongoing subscription fees for cloud-based monitoring service over two years**
- **Hapvida is one of Brazil’s largest health care providers, medical insurance companies and hospital owners, servicing 3.8m customers nationwide through 27 hospitals in 11 states**
- **Development marks the initial pilot roll out of HeraCARE, HMD’s SaaS and cloud monitoring service**
- **Both parties are collaborating to connect HeraBEAT to Hapvida’s Electronic Medical Record systems, allowing physicians and nurses to monitor data in real time**
- **Initiates HMD’s strategy of working with top tier healthcare providers and integrating solutions into their workflow, adding revenue for HeraMED via cloud integration and SaaS initiatives**
- **Hapvida has secured ANVISA approval for use in the pilot, the Brazilian equivalent to FDA approval – HeraMED will continue to work with Hapvida for full scale ANVISA approval as the trial progresses**

Medical technology company, **HeraMED Limited (ASX:HMD)** (“HeraMED” or the “Company”) advises that it has received its first order for its cloud based, SaaS pregnancy monitoring service, HeraCARE from Hapvida Saúde (“Hapvida”) one of Brazil’s largest healthcare providers, medical insurance companies and hospital owners.

The order, which is for an initial pilot trial is valued at US\$60,000. It encompasses 100 HeraBEAT smart ultrasound foetal heart rate monitors, software set up fees, a software development licencing kit and 24 months worth of monthly subscription fees for cloud based data monitoring services.

This is the maiden order for HeraMED’s SaaS and cloud-based platform, HeraCARE, which will be trialled at one of Hapvida’s hospitals over the coming months.

Hapvida services 3.8 million customers nationwide, through a network of 27 hospitals, 74 clinics, 17 ready-to-care sites, 72 diagnostics imaging units and 67 laboratory collection stations across 11 states. Hapvida completed an initial public offer on the Brazilian Stock Exchange in April 2018 (B3:HAPV3), raising US\$985m.

The pilot trial order, follows 12 months of stringent due diligence and testing by Hapvida, during which HeraMED personnel worked closely with Hapvida’s IT department to establish a cloud based service offering. HeraMED personnel worked closely with Hapvida’s IT department to integrate HeraCARE SaaS platform seamlessly into Hapvida’s systems.

This feature allows physicians and nurses to view real time patient data generated by the HeraBEAT system, through Hapvida’s Electronic Medical Records (EMR). Establishing this feature is the first instance that HeraMED is able to generate additional revenues through its SaaS based business model, HeraCARE.

The development provides validation of HeraMED’s model of working with top tier healthcare providers to integrate the HeraBEAT system into a hospital or clinics workflow. HeraMED will utilise its experience in working with Hapvida to further progress the HeraCARE platform, ensuring it is best in market.

The Company advises that it has also received ANVISA approval as part of this agreement. ANVISA approval is granted by the Brazilian Health Regulatory Agency. While the approval initially provides a limited licence to the use of HeraBEAT system with Hapvida, HeraMED will continue to work with Hapvida to obtain full-scale ANVISA approval as the pilot trial progresses.

**HeraMED Limited** ACN 626 295 314

**T:** +61 8 6189 1155 | **A:** Level 2, 46-50 Kings Park Road, West Perth WA 6005

**HeraMED CEO and Co-founder, Mr David Groberman said:** “This order, from an organisation as well established and credible as Hapvida, further validates the appeal and adaptability of HeraMED’s service offering.

“Whilst the order is still for an expanded pilot trial of the HeraBEAT device and our HeraCARE cloud based platform, the development reflects the growing appeal of our technology and the possibilities it has to integrate into large, established organisations globally.

“Receiving a product order for both HeraBEAT systems and HeraMED’s HeraCARE cloud based services from an organisation of Hapvida’s calibre is significant validation of our offering and business model.

“A considerable amount of work has gone into securing this order and the Company looks forward to updating shareholders as it progresses. HeraMED is in a transformational phase of growth and will provide regular updates to shareholders on future developments.”

**-ENDS-**

HeraMED Limited

CEO and Co-Founder

David Groberman

M:+972-52-6991188

E: David@hera-med.com

Company Secretary

Stephen Buckley

T: +61 (0)8 6189 1155

E: stephen@companysecsol.com.au

**About HeraMED Limited (ASX:HMD):**

HeraMED Limited is an innovative medical technology company delivering smart pregnancy monitoring solutions for home and professional use. HeraMED provides peace of mind to expecting parents by solving problems associated with the reliability of pre-natal analysis, as well as the cost and shortage in fundamental services through end-to-end medical grade solutions utilising monitoring devices, cloud based platforms and AI capabilities.

HeraMED is commercialising the worlds most advanced, smart medical grade ultrasound monitoring device HeraBEAT. The device has passed multiple clinical trials and secured approval by key regulatory bodies including TGA (Australia), CE (Europe) and AMAR (Israel) for commercial sale.

The Company has partnerships with two leading medical organisations, the Mayo Clinic and TEVA Pharmaceutical Industries Inc. (NYSE: TEVA). HeraMED diversifying its product range and services with the launch of SaaS services and cloud based monitoring systems.